BioSpace1h
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
Precision Medicine Online1h
Alnylam's Qfitlia, Siemens Antithrombin CDx Garner FDA Approval for Treating Hemophilia A/B
The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.
Alnylam presents new data from HELIOS-B Phase 3 trial
Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...